Abstract 19179: Impact of the 2013 ACC/AHA Cholesterol Management Guideline: Have Treatment Patterns Evolved After 2 Years?
Objective: To characterize changes in statin treatment patterns in the 2 years after the release of the 2013 ACC/AHA cholesterol management guideline in a commercially insured/Medicare Advantage population.
Methods: Using administrative claim and laboratory result data from the HealthCore Integrated Research Database, statin use was captured on a quarterly basis during the 1 year before and 2 years after release of the ACC/AHA guideline. Individuals were classified into the 4 statin benefit groups (SBGs), as delineated in the guideline. Patients new to statins were identified independently during each quarter and their treatment patterns described.
Results: An average of 199,391 patients were identified across the 4 SBGs during each quarter and an average of 3,596 were new statin users. New users were mostly men (59%), with an average age of 61 years. Results are shown in the Figure. In SBG1, high-intensity statin use in patients ≤75 years increased from an annual average of 19.4% before to 23.6% and 31.1% in years 1 and 2 after guideline release, respectively. In SBG2, there was a gradual increase in high-intensity statin use across the 2 years following introduction of the guideline. An increase in high-intensity statin use over the 2 years post-guideline release was also observed in SBG3 for patients with a 10-year ASCVD risk ≥7.5%, but little change was seen for moderate-intensity statin use for patients with ASCVD risk <7.5%. In SBG4, a small increase in moderate- to high-intensity statin use was observed.
Conclusions: Based on our study results, the message around utilization of high-intensity statins associated with the 2013 ACC/AHA guideline appears to be steadily adopted by clinicians in the 2 years following its release. A year-over-year increase in the utilization of high-intensity statins for the SBGs in which they are recommended was observed among new statin users. This increase was most marked in the use of high-intensity statins in ASCVD patients.
Author Disclosures: T. Olufade: Employment; Significant; Employee of AstraZeneca. D. Anzalone: Employment; Significant; Employee of AstraZeneca. S. Zhou: Employment; Significant; Employee of HealthCore. V. Willey: Employment; Significant; Employee of HealthCore. M.J. Cziraky: Employment; Significant; Employee of HealthCore.
- © 2016 by American Heart Association, Inc.